Reena's questions to Travere Therapeutics Inc (TVTX) leadership • Q3 2024
Question
Reena, on for Yigal Nochomovitz at Citigroup Inc., asked for commentary on FILSPARI's compliance and adherence metrics under the monthly REMS monitoring and how these might change with a reduction in monitoring frequency.
Answer
Chief Commercial Officer Peter Heerma stated that compliance and persistency rates are 'really high,' which he attributed to patients experiencing positive results and reaching treatment targets. President and CEO Dr. Eric Dube added that if monitoring frequency is reduced, the company would ensure patients continue to receive the right level of support and engagement.